|
Asthma candidate reaches primary endpoint
PMLiVE Roche has announced that MILLY, a phase II study of its investigational asthma treatment lebrikizumab, has reached its primary endpoint of creating a statistically significant increase in lung function in adults with uncontrolled asthma. … Roche excited about first personalised asthma drug |
View full post on asthma – Google News